title: Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.
abstract: OBJECTIVE
  We investigated the correlation between protein expression of Aurora-A with hormone receptor expression and clinicopathological parameters in ovarian, breast and prostate cancer.
  
  
  METHODS
  Subcellular expression of Aurora-A, and androgen receptor (AR), oestrogen receptor (ER) and progesterone receptor (PR) expression, were examined by immunohistochemistry in human tissue microarrays of the three cancer types and by Western blot in cancer cell lines and selected patient tissues.
  
  
  RESULTS
  Subgroups of all three cancer types exhibited both nuclear and cytoplasmic expression of Aurora-A. Nuclear presence of Aurora-A was observed in ER positive and negative breast cancer cell lines and tissues. Eighteen of the 126 (14%) tumour tissues that showed nuclear expression of Aurora-A were strongly associated with ER and PR positive breast tumours (p = 0.001). Cytoplasmic expression of AR and Aurora-A was strongly associated in prostate cancer tissues (45% versus 0, p = 0.015). Ovarian tumours (n = 45) with Aurora-A nuclear expression had decreased patient survival (mean survival, 29.5 versus 106.7 months; p < 0.0005) and showed a significant association with recurrence-free survival (mean survival 19.7 versus 95.9 months; p = 0.002).
  
  
  CONCLUSIONS
  Association between nuclear Aurora-A with hormone receptors in breast cancer and with poor clinical outcome in ovarian cancer suggests the significance of active Aurora-A in disease initiation and progression.
authors.affiliation: Cancer Science Institute, National University of Singapore. kaks23@yahoo.com
authors.forename: Kakoli
authors.initials: K
authors.lastname: Das
authors.forename: Pia Donna Nitullano
authors.initials: PD
authors.lastname: Lorena
authors.forename: Lai Kuan
authors.initials: LK
authors.lastname: Ng
authors.forename: Liang
authors.initials: L
authors.lastname: Shen
authors.forename: Diana
authors.initials: D
authors.lastname: Lim
authors.forename: Woei Yun
authors.initials: WY
authors.lastname: Siow
authors.forename: Kothandaraman
authors.initials: K
authors.lastname: Narasimhan
authors.forename: Ming
authors.initials: M
authors.lastname: Teh
authors.forename: Mahesh
authors.initials: M
authors.lastname: Choolani
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Putti
authors.forename: Manuel
authors.initials: M
authors.lastname: Salto-Tellez
mesh_terms: D064127:Aurora Kinases; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis*; D011944:Receptors, Androgen / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases